The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses
Open accessAbstract
Summary Foxp3+ T regulatory (Treg) cells regulate immune responses and maintain self-tolerance. Recent work shows that Treg cells are comprised of many subpopulations with specialized regulatory functions. Here we identified Foxp3+ T cells expressing the co-inhibitory molecule TIGIT as a distinct Treg cell subset that specifically suppresses pro-inflammatory T helper 1 (Th1) and Th17 cell, but not Th2 cell responses. Transcriptional profiling characterized TIGIT+ Treg cells as an activated Treg subset with high expression of Treg signature genes. Ligation of TIGIT on Treg cells induced expression of the effector molecule fibrinogen-like protein 2 (Fgl2), which promoted Treg cell-mediated suppression of T effector cell proliferation. In addition, Fgl2 was necessary to prevent suppression of Th2 cell cytokine production in a model of allergic airway inflammation. TIGIT expression therefore identifies a Treg cell subset that demonstrates selectivity for suppression of Th1 and Th17 cell but not Th2 cell responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 2×
“KI reporter mice (Bettelli et al., 2006), Tigit / mice (Levin et al.”
BackgroundSelf-citationInterleukin-10-deficient mice develop chronic enterocolitis
Kühn, R., Löhler, J., Rennick, D., Rajewsky, K., & Müller, W. (1993) · Cell · doi:10.1016/0092-8674(93)80068-p · Cited by 4,274
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,088
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,639
Brunkow, M. E., Jeffery, E. W., Hjerrild, K. A., Paeper, B., Clark, L. B., Yasayko, S.-A., Wilkinson, J. E., Galas, D., Ziegler, S. F., & Ramsdell, F. (2001) · Nature Genetics · doi:10.1038/83784 · Cited by 2,636
Regulatory T Cell Lineage Specification by the Forkhead Transcription Factor Foxp3
Fontenot, J. D., Rasmussen, J. P., Williams, L. M., Dooley, J. L., Farr, A. G., & Rudensky, A. Y. (2005) · Immunity · doi:10.1016/j.immuni.2005.01.016 · Cited by 2,279
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
Self-citationWildin, R. S., Ramsdell, F., Peake, J., Faravelli, F., Casanova, J.-L., Buist, N., Levy-Lahad, E., Mazzella, M., Goulet, O., Perroni, L., et al. (2001) · Nature Genetics · doi:10.1038/83707 · Cited by 1,922
The Immunological Genome Project: networks of gene expression in immune cells
The Immunological Genome Project Consortium, Heng, T. S. P., Painter, M. W., Elpek, K., Lukacs-Kornek, V., Mauermann, N., Turley, S. J., Koller, D., Kim, F. S., Wagers, A. J., et al. (2008) · Nature Immunology · doi:10.1038/ni1008-1091 · Cited by 1,864
Self-citation
Cited by
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Self-citationSingle-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment
Azizi, E., Carr, A. J., Plitas, G., Cornish, A. E., Konopacki, C., Prabhakaran, S., Nainys, J., Wu, K., Kiseliovas, V., Setty, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.060 · Cited by 1,976
Lambrecht, B. N., & Hammad, H. (2015) · Nature Immunology · doi:10.1038/ni.3049 · Cited by 1,673
Rothhammer, V., & Quintana, F. J. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0125-8 · Cited by 1,197
Self-citationZhang, Q., Bi, J., Zheng, X., Chen, Y., Wang, H., Wu, W., Wang, Z., Wu, Q., Peng, H., Wei, H., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0132-0 · Cited by 1,122
Regulation of the immune response by the aryl hydrocarbon receptor
Gutiérrez-Vázquez, C., & Quintana, F. J. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.012 · Cited by 985
Self-citationCoinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
Self-citationMartin, J. C., Chang, C., Boschetti, G., Ungaro, R., Giri, M., Grout, J. A., Gettler, K., Chuang, L.-S., Nayar, S., Greenstein, A. J., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.008 · Cited by 872
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871
Chauvin, J.-M., & Zarour, H. M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000957 · Cited by 794
TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
Chauvin, J.-M., Pagliano, O., Fourcade, J., Sun, Z., Wang, H., Sander, C., Kirkwood, J. M., Chen, T.-H. T., Maurer, M., Korman, A. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80445 · Cited by 784
Metabolic coordination of T cell quiescence and activation
Chapman, N. M., Boothby, M. R., & Chi, H. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0203-y · Cited by 751
De Simone, M., Arrigoni, A., Rossetti, G., Gruarin, P., Ranzani, V., Politano, C., Bonnal, R. J. P., Provasi, E., Sarnicola, M. L., Panzeri, I., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.021 · Cited by 687
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01282-8 · Cited by 591
TIGIT as an emerging immune checkpoint
Harjunpää, H., & Guillerey, C. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13407 · Cited by 552
TIGIT predominantly regulates the immune response via regulatory T cells
Kurtulus, S., Sakuishi, K., Ngiow, S.-F., Joller, N., Tan, D. J., Teng, M. W. L., Smyth, M. J., Kuchroo, V. K., & Anderson, A. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81187 · Cited by 551
Self-citationRetractedInhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
Andrews, L. P., Yano, H., & Vignali, D. A. A. (2019) · Nature Immunology · doi:10.1038/s41590-019-0512-0 · Cited by 543
Mitochondrial complex III is essential for suppressive function of regulatory T cells
Weinberg, S. E., Singer, B. D., Steinert, E. M., Martinez, C. A., Mehta, M. M., Martínez-Reyes, I., Gao, P., Helmin, K. A., Abdala-Valencia, H., Sena, L. A., et al. (2019) · Nature · doi:10.1038/s41586-018-0846-z · Cited by 494
Reversing T-cell Dysfunction and Exhaustion in Cancer
Zarour, H. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1849 · Cited by 462
Immunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
TIGIT and CD 96: new checkpoint receptor targets for cancer immunotherapy
Dougall, W. C., Kurtulus, S., Smyth, M. J., & Anderson, A. C. (2017) · Immunological Reviews · doi:10.1111/imr.12518 · Cited by 435
TIGIT: A Key Inhibitor of the Cancer Immunity Cycle
Manieri, N. A., Chiang, E. Y., & Grogan, J. L. (2017) · Trends in Immunology · doi:10.1016/j.it.2016.10.002 · Cited by 415
Treg Heterogeneity, Function, and Homeostasis
Shevyrev, D., & Tereshchenko, V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03100 · Cited by 404
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Cai, L., Li, Y., Tan, J., Xu, L., & Li, Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01499-1 · Cited by 391
Banta, K. L., Xu, X., Chitre, A. S., Au-Yeung, A., Takahashi, C., O’Gorman, W. E., Wu, T. D., Mittman, S., Cubas, R., Comps-Agrar, L., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.02.005 · Cited by 370
Hildreth, A. D., Ma, F., Wong, Y. Y., Sun, R., Pellegrini, M., & O’Sullivan, T. E. (2021) · Nature Immunology · doi:10.1038/s41590-021-00922-4 · Cited by 359
Rotte, A., Jin, J. Y., & Lemaire, V. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx686 · Cited by 344
T Cell Dysfunction in Cancer Immunity and Immunotherapy
Xia, A., Zhang, Y., Xu, J., Yin, T., & Lu, X.-J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01719 · Cited by 341
Sodium chloride inhibits the suppressive function of FOXP3+ regulatory T cells
Hernandez, A. L., Kitz, A., Wu, C., Lowther, D. E., Rodriguez, D. M., Vudattu, N., Deng, S., Herold, K. C., Kuchroo, V. K., Kleinewietfeld, M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81151 · Cited by 338
Self-citationMechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Granier, C., De Guillebon, E., Blanc, C., Roussel, H., Badoual, C., Colin, E., Saldmann, A., Gey, A., Oudard, S., & Tartour, E. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000213 · Cited by 324
Chew, G. M., Fujita, T., Webb, G. M., Burwitz, B. J., Wu, H. L., Reed, J. S., Hammond, K. B., Clayton, K. L., Ishii, N., Abdel-Mohsen, M., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005349 · Cited by 323
Regulatory T Cell Specificity Directs Tolerance versus Allergy against Aeroantigens in Humans
Bacher, P., Heinrich, F., Stervbo, U., Nienen, M., Vahldieck, M., Iwert, C., Vogt, K., Kollet, J., Babel, N., Sawitzki, B., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.050 · Cited by 319
Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells
Sasidharan Nair, V., & Elkord, E. (2018) · Immunology & Cell Biology · doi:10.1111/imcb.1003 · Cited by 298
Haist, M., Stege, H., Grabbe, S., & Bros, M. (2021) · Cancers · doi:10.3390/cancers13020210 · Cited by 295
The PI3K/AKT signaling pathway in regulatory T-cell development, stability, and function
Pompura, S. L., & Dominguez-Villar, M. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.2mir0817-349r · Cited by 288
Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226
Fuhrman, C. A., Yeh, W.-I., Seay, H. R., Saikumar Lakshmi, P., Chopra, G., Zhang, L., Perry, D. J., McClymont, S. A., Yadav, M., Lopez, M.-C., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402381 · Cited by 262
PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
Tan, C. L., Kuchroo, J. R., Sage, P. T., Liang, D., Francisco, L. M., Buck, J., Thaker, Y. R., Zhang, Q., McArdel, S. L., Juneja, V. R., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20182232 · Cited by 258
Self-citationPD-1 marks dysfunctional regulatory T cells in malignant gliomas
Lowther, D. E., Goods, B. A., Lucca, L. E., Lerner, B. A., Raddassi, K., van Dijk, D., Hernandez, A. L., Duan, X., Gunel, M., Coric, V., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85935 · Cited by 253
Self-citationMolecular pathways: targeting CD96 and TIGIT for cancer immunotherapy
Blake, S. J., Dougall, W. C., Miles, J. J., Teng, M. W. L., & Smyth, M. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0933 · Cited by 223
The role of cancer-derived microRNAs in cancer immune escape
Yi, M., Xu, L., Jiao, Y., Luo, S., Li, A., & Wu, K. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00848-8 · Cited by 221
Wang, B., Zhang, W., Jankovic, V., Golubov, J., Poon, P., Oswald, E. M., Gurer, C., Wei, J., Ramos, I., Wu, Q., et al. (2018) · Science Immunology · doi:10.1126/sciimmunol.aat7061 · Cited by 167
Understanding the Role of T Cells in CNS Homeostasis
Ellwardt, E., Walsh, J. T., Kipnis, J., & Zipp, F. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.12.008 · Cited by 156
Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy
Chuckran, C. A., Liu, C., Bruno, T. C., Workman, C. J., & Vignali, D. A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000967 · Cited by 147
NADPH oxidase deficiency underlies dysfunction of aged CD8+ Tregs
Wen, Z., Shimojima, Y., Shirai, T., Li, Y., Ju, J., Yang, Z., Tian, L., Goronzy, J. J., & Weyand, C. M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84181 · Cited by 146
“Young donors were 20 to 30 protein 2 (40).”
BackgroundCoexpression of TIGIT and FCRL3 Identifies Helios+ Human Memory Regulatory T Cells
Bin Dhuban, K., d’Hennezel, E., Nashi, E., Bar-Or, A., Rieder, S., Shevach, E. M., Nagata, S., & Piccirillo, C. A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401803 · Cited by 117
Kumar, P., Saini, S., & Prabhakar, B. S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.01.006 · Cited by 117
Cellular and molecular mechanisms of CD8(+) T cell differentiation, dysfunction and exhaustion
Verdon, D. J., Mulazzani, M., & Jenkins, M. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197357 · Cited by 98
Treg cell therapy: How cell heterogeneity can make the difference
Giganti, G., Atif, M., Mohseni, Y., Mastronicola, D., Grageda, N., Povoleri, G. A., Miyara, M., & Scottà, C. (2021) · European Journal of Immunology · doi:10.1002/eji.201948131 · Cited by 82
Mao, L., Xiao, Y., Yang, Q.-C., Yang, S.-C., Yang, L.-L., & Sun, Z.-J. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105472 · Cited by 68
Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55
Optimized CRISPR-mediated gene knockin reveals FOXP3-independent maintenance of human Treg identity
Lam, A. J., Lin, D. T. S., Gillies, J. K., Uday, P., Pesenacker, A. M., Kobor, M. S., & Levings, M. K. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109494 · Cited by 52
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Roy, D., Gilmour, C., Patnaik, S., & Wang, L. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264327 · Cited by 53
Innate Control of Tissue-Reparative Human Regulatory T Cells
Lam, A. J., MacDonald, K. N., Pesenacker, A. M., Juvet, S. C., Morishita, K. A., Bressler, B., iGenoMed Consortium, Pan, J. G., Sidhu, S. S., Rioux, J. D., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801330 · Cited by 47
Impact of the gut microbiota on enhancer accessibility in gut intraepithelial lymphocytes
Semenkovich, N. P., Planer, J. D., Ahern, P. P., Griffin, N. W., Lin, C. Y., & Gordon, J. I. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617793113 · Cited by 45
CD30+OX40+ Treg is associated with improved overall survival in colorectal cancer
Lam, J. H., Hong, M., Koo, S.-L., Chua, C. W. L., Lim, K. L., Wee, F., Wan, W. K., Leow, W. Q., Yeo, J. G., Tan, I. B. H., et al. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-021-02859-x · Cited by 31
Bone marrow immune cells respond to fluctuating nutritional stress to constrain weight regain
Zhou, H.-Y., Feng, X., Wang, L.-W., Zhou, R., Sun, H., Chen, X., Lu, R.-B., Huang, Y., Guo, Q., & Luo, X.-H. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.08.009 · Cited by 30
The Nr4a family regulates intrahepatic Treg proliferation and liver fibrosis in MASLD models
Aki, D., Hayakawa, T., Srirat, T., Shichino, S., Ito, M., Saitoh, S.-I., Mise-Omata, S., & Yoshimura, A. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175305 · Cited by 22
“The 1_0 cluster had high expression of Tigit , Ctla4 , Il10 , and Fgl2 , all of which were shown to be expressed on immunosuppressive Tregs (33).”
Ferreira, R. C., Rainbow, D. B., Rubio García, A., Pekalski, M. L., Porter, L., Oliveira, J. J., Waldron-Lynch, F., Wicker, L. S., & Todd, J. A. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.03.002 · Cited by 19
“However, we note in two of these studies [69,71] that naive Tregs were not excluded from the sorted TIGIT Tregs used in the suppression assays and, therefore,may have diluted the suppressive capacity, when considered on a per cell basis, of the mTregs within the sorted TIGIT Treg population.”
ResultRegulatory T Cells: Central Concepts from Ontogeny to Therapy
Khor, B. (2017) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2016.07.003 · Cited by 15
Metadata
- Authors
- Joller, N., Lozano, E., Burkett, P. R., Patel, B., Xiao, S., Zhu, C., Xia, J., Tan, T. G., Sefik, E., Yajnik, V., Sharpe, A. H., Quintana, F. J., Mathis, D., Benoist, C., Hafler, D. A., & Kuchroo, V. K.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 40
- Issue
- 4
- Pages
- 569-581
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W1983812780
- Cited by
- 955
- References
- 34
- FWCI
- 17.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.